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ARTICLE
Urinary tract colonization is enhanced by a plasmid
that regulates uropathogenic Acinetobacter
baumannii chromosomal genes
Gisela Di Venanzio 1, Ana L. Flores-Mireles 2,10, Juan J. Calix 3, M. Florencia Haurat1, Nichollas E. Scott4,
Lauren D. Palmer 5, Robert F. Potter6, Michael E. Hibbing2, Laura Friedman7, Bin Wang6,
Gautam Dantas 1,6,8,9, Eric P. Skaar5, Scott J. Hultgren 2 & Mario F. Feldman1
Multidrug resistant (MDR) Acinetobacter baumannii poses a growing threat to global health.
Research on Acinetobacter pathogenesis has primarily focused on pneumonia and blood-
stream infections, even though one in ﬁve A. baumannii strains are isolated from urinary sites.
In this study, we highlight the role of A. baumannii as a uropathogen. We develop the ﬁrst
A. baumannii catheter-associated urinary tract infection (CAUTI) murine model using UPAB1,
a recent MDR urinary isolate. UPAB1 carries the plasmid pAB5, a member of the family
of large conjugative plasmids that represses the type VI secretion system (T6SS) in multiple
Acinetobacter strains. pAB5 confers niche speciﬁcity, as its carriage improves UPAB1
survival in a CAUTI model and decreases virulence in a pneumonia model. Comparative
proteomic and transcriptomic analyses show that pAB5 regulates the expression of multiple
chromosomally-encoded virulence factors besides T6SS. Our results demonstrate that
plasmids can impact bacterial infections by controlling the expression of chromosomal genes.
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Human bacterial commensals and obligate pathogens haveevolved features that facilitate their survival in a speciﬁchabitat. In many cases, these microbial factors are also
determinants of virulence and dictate the spectrum of disease
associated with the pathogen1. For example, some structural
features of Streptococcus pneumoniae capsule appear to be
essential for colonization of the human respiratory tract, but
negatively inﬂuence survival in blood2. In contrast, incidental
pathogens with environmental, non-human reservoirs are largely
considered to be “niche nonspeciﬁc opportunistic pathogens”.
These pathogens generally cause a wide spectrum of disease
dependent on permissive hosts, such as patients that are immu-
nocompromised or critically ill, suffer from breaks in normal
immune barriers, or whose microbiomes are perturbed by anti-
microbial therapy3,4. The Gram-negative bacterium Acinetobacter
baumannii is generally considered an opportunistic pathogen
with no speciﬁcity for a particular niche. As a pathogen, it is
primarily associated with nosocomial infections, mainly hospital
acquired pneumonia, bacteremia, soft tissue infections, and
urinary tract infections (UTI)5, although cases of community
acquired infections have been described6. Furthermore, A. bau-
mannii is recognized as a serious health threat worldwide due to
the emerging prevalence of clinical isolates that are multidrug
resistant (MDR). Indeed, because A. baumannii MDR rates are
at least fourfold higher than those for Pseudomonas aeruginosa,
the second most MDR Gram-negative pathogen7, the World
Health Organization identiﬁed A. baumannii as a top priority for
the research and development of new antimicrobial therapies8.
However, an incomplete understanding of A. baumannii ecology
and pathophysiology limits the development of alternative ther-
apeutic strategies.
The two A. baumannii strains most commonly used in
pathogenesis research, ATCC19606 and ATCC179789,10, are
non-MDR, lab-domesticated strains that were isolated over
50 years ago. These strains exhibit reduced virulence compared
to more recent clinical isolates11,12 and lack virulence factors
identiﬁed in modern A. baumannii strains, such as the recently
described protease CpaA13. In order to employ more relevant
strains, recent research efforts have adopted contemporary model
strains, such as the hypervirulent isolates Ab5075 and LAC-414,15.
Under the assumption that pathogenic isolates are equally com-
petent in establishing infection in different anatomical niches in
a permissive host, Acinetobacter strains are often investigated
using infection models that do not match their clinical history.
For example, strain Ab5075, isolated in 2008 from a bone
infection, has been employed to investigate respiratory infec-
tions14. A. baumannii virulence is principally investigated in vivo
using murine pneumonia15 and sepsis models16, with only a few
reports using soft tissue infection models17. Notably, despite early
reports highlighting A. baumannii as the principal cause of
catheter-associated UTI (CAUTI) in some clinical settings18,19,
there is no established model to investigate A. baumannii infec-
tion in the unique environment of the urinary tract. Thus, current
infection models may not be adequate to investigate the full
spectrum of Acinetobacter disease.
Here, we report that up to one-ﬁfth of A. baumannii isolates
are obtained from urinary sources, according to a local retro-
spective study and a systematic review of literature from the last
25 years. To investigate this signiﬁcant manifestation of A. bau-
mannii disease, we develop a murine model of A. baumannii
CAUTI using a recent MDR UTI isolate, UPAB1. We demon-
strate that UPAB1 is able to establish early implant and bladder
colonization, dependent on chaperone-usher pathway (CUP) pili.
We discovered that UPAB1 harbors a large conjugative plasmid,
pAB5, and showed that pAB5 increases UPAB1 virulence in the
CAUTI model but is detrimental in a murine pneumonia model.
We linked this behavior to the remarkable ability of pAB5
to impact the expression of multiple chromosomally-encoded
virulence factors, such as pili, exopolysaccharides, and protein
secretion systems.
Results
The urinary tract is a major source of A. baumannii isolates.
We performed a retrospective analysis of all Acinetobacter isolates
identiﬁed in the BJC Healthcare System (BJC) from January 2007
through August 2017. Of 2309 identiﬁed “Acinetobacter
calcoaceticus-baumannii complex” (Acbc) cases, 22.2% (n= 505)
were from urinary sources, compared to 33.9% (n= 771), 31.9%
(n= 726), 10.4% (n= 237), and 1.5% (n= 34) from respiratory,
soft tissue/musculoskeletal (SST/MSK), endovascular, and “other”
sources, respectively (Fig. 1). To expand our investigation glob-
ally, we performed a systematic review of clinical studies pub-
lished since 1995, which document the anatomical site of
isolation of A. baumannii or Acbc specimens. Data were compiled
on over 19,000 cases identiﬁed as early as 1990, reported in our
local study and 12 international clinical studies (Fig. 1, Supple-
mentary Table 1). As in our local ﬁndings, respiratory and SST/
MSK specimens were the most common isolates worldwide,
composing 39.5% and 22.7% of total isolates, respectively. The
percentages comprised of urinary isolates varied from study to
study (6.1–29.3%), but overall, 17.1% of total isolates (3410 of
19957) were obtained from urinary sources. Thus, despite this
clinical relevance, the role of A. baumannii as a uropathogen has
been largely neglected.
A CAUTI murine model for Acinetobacter. Approximately one-
in-ﬁve A. baumannii isolates are derived from urinary sources.
Though only ~2% of total UTIs are attributed to Acinetobacter in
global surveillance studies, various single-center studies report
that Acinetobacter is a leading cause of CAUTI18, especially
in intensive care units19. However, there is no model to study
A. baumannii uropathogenesis. A. baumannii infections are
commonly associated with the presence of indwelling medical
devices, such as endotracheal tubes or central venous lines, and
up to 60% of A. baumannii urine isolates are from patients with
indwelling or intermittent catheters20. To simulate this clinical
Acinetobacter scenario, we adapted a murine CAUTI model
frequently used to investigate uropathogenic Escherichia coli
(UPEC), Enterococcus faecalis, methicillin-resistant Staphylo-
coccus aureus (MRSA) and Group B Streptococcus urinary
infections21,22. We evaluated the ability of two A. baumannii
urinary isolates, ATCC19606 (“19606”) and UPAB1, to colonize
the bladders and kidneys of mice. 19606 is a urinary isolate
obtained in 1967 and routinely used to study A. baumannii
virulence in pneumonia and septicemia murine models12,23. In
contrast, UPAB1 is an MDR isolate obtained from an ambulatory
female patient with an uncomplicated UTI in 2016. Bacteria were
inoculated transurethrally after a small piece of silicone tubing
(implant) was placed in each mouse urethra. Colonization of the
implants, bladders and kidneys was analyzed. Our results show
that at 24 h post infection (hpi), 19606 was nearly cleared from
infected mice, while bacterial burden increased 5-logs on implants
and bladders recovered from UPAB1-infected mice (Fig. 2a).
Fluorescence microscopy conﬁrmed the presence of UPAB1 (in
red or Ab) on the luminal urothelial surface and on the outer
surface of silicone implants (Fig. 2b, left panel). Catheterization
elicits an inﬂammatory response in the human bladder, resulting
in the release of ﬁbrinogen (Fg) into the bladder lumen, ulti-
mately coating the catheter24. Known uropathogens, E. faecalis
and S. aureus, express the Fg binding adhesins, EbpA and ClfB,
respectively, that mediate binding and bioﬁlm formation on the
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Fg-coated catheters21,22. UPAB1 co-localized with aggregates of
Fg (green ﬂuorescence) (Fig. 2b, right panel), similar to what has
been previously observed in corresponding models with E. fae-
calis and MRSA21,22. Thus, UPAB1 infects the bladder and the
catheter in a murine CAUTI model, in a similar manner to other
uropathogens.
UPEC and MRSA are able to grow in healthy human urine
in vitro21,25 so we hypothesized that the inter-strain differences in
the CAUTI model could be dictated by differential growth in
urine. Indeed, 19606 displayed poorer growth and lower ﬁnal
bacterial concentrations in pooled healthy human urine,
compared to UPAB1 (Fig. 2c), despite both strains displaying
indistinguishable growth in rich media (Supplementary Fig. 1).
Furthermore, UPAB1 grew better in pooled human urine when
compared to established uropathogenic strains of UPEC and
MRSA (Fig. 2c). Altogether, these results indicate that UPAB1 is
a bona-ﬁde uropathogenic A. baumannii (UPAB) strain.
Adhesion to catheters and urothelial cells is widely accepted
as an essential step in establishing a CAUTI and/or UTI26,27.
UPEC strains employ CUP pili to establish colonization in the
bladder25,28. To validate the CAUTI model as a tool for
identifying factors involved in A. baumannii uropathogenesis,
we sequenced the 3.9 Mbp genome of UPAB1 (accession number
CP032215-CP032220). We found that the UPAB1 genome
harbors two loci encoding putative CUP pili, that we termed
CUP1 and CUP2 (Fig. 3a). The CUP1 locus is homologous to the
recently described type I CUP pilus locus, prpABCD29, while
the CUP2 locus has not been previously described. To assess
whether these CUP pili contribute to UPAB1 uropathogenesis, we
constructed the UPAB1 ΔCUP1,2 strain, which lacks the ABCD
genes from CUP1 and CUP2 pili operons (Fig. 3a). Electron
microscopy imaging of WT UPAB1 bacteria revealed distinct
surface appendages, which were largely absent from the surfaces
of ΔCUP1,2 bacteria (Fig. 3b). Despite both strains displaying
indistinguishable growth in rich medium and healthy human
urine (Supplementary Fig. 2), ΔCUP1,2 strains displayed a 2-log
reduction of bacterial burden on the implant and a 1-log
reduction in the bladder, compared to WT UPAB1 in the CAUTI
model (Fig. 3c). Altogether the CAUTI model was able to
reveal that CUP pili, known adhesion factors for other bacterial
uropathogens, are likely involved in establishing A. baumannii
colonization of the urinary tract, validating the utility of the
model to investigate A. baumannii uropathogenesis.
Plasmid pAB5 dictates UPAB1 niche-speciﬁc virulence. Having
established the CAUTI model to evaluate Acinetobacter uro-
pathogenesis, we analyzed UPAB1 for other potential virulence
factors. Genome sequencing revealed UPAB1 contains two
endogenous plasmids. One of these plasmids, named pAB5
(Accession numbers CP032216, CP032218 and CP032219) shares
high homology with other plasmids belonging to the Large
Conjugative Plasmid (LCP) family, pAB3 and pAB430,31. LCPs
contain a resistance island that encodes multiple putative anti-
microbial resistance genes, and genes encoding the two TetR
transcriptional regulators implicated in repression of the type VI
secretion system (T6SS) in other A. baumannii strains30.
Accordingly, a UPAB1 derivative lacking pAB5, UPAB1p-, dis-
played increased susceptibility to multiple antibiotics and acti-
vation of the T6SS, as observed by secretion of the T6SS-
associated protein Hcp (Supplementary Fig. 3).
Repression of T6SS and/or other bacterial genes by pAB5
could impact the pathogenic potential of UPAB1. Alternatively,
pAB5 could affect virulence by carrying virulence factors and/or
pathogenicity islands, as has been extensively described in
Yersinia, Shigella, and other bacterial pathogens32,33. Thus, we
examined whether pAB5 inﬂuenced UPAB1 uropathogenesis.
Wild-type UPAB1 (WT UPAB1) and UPAB1p- displayed
comparable growth in vitro in both rich medium and urine from
healthy donors (Supplementary Fig. 4), suggesting that carrying
a large plasmid does not inﬂuence bacterial growth. In the CAUTI
model, WT UPAB1 showed signiﬁcantly higher bacterial burdens
on the implant and in the bladder of the infected mice compared






























826 1/1997–12/2001 Latin America
58 2001 Nigeria
1532 1991–1996 Spain
7046 1/1990–11/1994 Hong Kong
17.1% 39.5% 22.7% 13.2% *
Fig. 1 Urinary tract is an important source of A. baumannii clinical isolates. Graph depicts the distribution of isolates obtained from each anatomical site,
listed by study and a “pooled total”. Studies included in the analysis are listed on the left axis, with the current study underlined71–82. Percentage of pooled
total isolates corresponding to each anatomical site, is noted in the top-most bar. Table along right axis lists the number of isolates included, the dates of
isolate collection, and the country/region where each study was performed. *, “other” isolates comprise 7.5% of “Pooled Total” isolates. SST/MSK: soft
tissue/musculoskeletal. Source data are provided as a Source Data ﬁle
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to UPAB1p- (Fig. 4), demonstrating that the presence of pAB5
increases the virulence of Acinetobacter in CAUTI. We then tested
if pAB5 carriage results in increased virulence in the acute
pneumonia model, the most common model for evaluating A.
baumannii pathogenesis15. Unexpectedly, 36 h after intranasal
inoculation, we observed that mice infected with plasmid-
containing UPAB1 WT carried one to four logs less bacterial
burden in their lungs, spleens, livers, kidneys and hearts,
compared to mice infected with UPAB1p- (Fig. 5). The differences
in bacterial burdens were less pronounced in the lung than in the
other organs, indicating that pAB5 effects are ampliﬁed during
bacterial dissemination. Moreover, mice infected with UPAB1p-
displayed 60% survival at 36 hpi, in contrast to 100% survival in
mice infected with WT UPAB1. We appreciated no in vivo loss of
pAB5, as determined by plating recovered bacteria on both LB
agar and agar containing kanamycin and gentamycin, whose
resistance cassettes are encoded on pAB5. In summary, pAB5
conferred improved UPAB1 colonization in the CAUTI model
while attenuating the strain in a pneumonia model.
pAB5 controls the expression of chromosomal factors in
UPAB1. Our results show that pAB5 confers UPAB1 niche-
speciﬁc virulence. To identify whether potential effectors or
secreted factors are differentially regulated by pAB5, we utilized a
quantitative proteomics approach34. WT UPAB1 and UPAB1p-
were grown in minimal medium to facilitate protein identiﬁca-
tion. As expected, several components and putative effectors of
the T6SS were found in signiﬁcantly lower levels in the presence
of pAB5 (Fig. 6a and Supplementary Table 2). Additionally, levels
of proteins involved in CUP1 and CUP2 pili assembly were
reduced in WT UPAB1 (Fig. 6a), indicating that pAB5 can
modulate expression of other chromosomally-encoded proteins,
including some implicated in bioﬁlm formation and adherence in
other characterized uropathogens.
To identify additional UPAB1 factors differentially expressed
in the presence of pAB5 we performed proteomic and
transcriptomic experiments on whole bacterial cells. Since
bacterial inocula used in murine experiments were prepared








































































Fig. 2 A. baumannii UPAB1 strain is an uropathogen. a Catheter-implanted mice were infected with ~2 × 108 CFU of the indicated strains. Following 24 h of
infection, total numbers of CFU recovered were determined for the implants, bladders and kidneys. Each symbol represents an individual mouse. For each
strain, the median value is shown as the horizontal line. Statistical analyses were performed using the Mann–Whitney U test, *p < 0.05. b Left panel:
Representative images of an infected mouse bladder with implants at 24 hpi. Sections were stained for cell nuclei (blue), ﬁbrinogen (green), and UPAB1
(red). Dotted white lines denote the separation of bladder tissue (LP: Lamina Propria) from lumen (LM). Bar: 20 µm. Right panel: UPAB1 colocalizes with
ﬁbrinogen deposited on implants at 24 hpi. c Growth curves of UPAB1, 19606, MRSA 1369, E. coli UTI89 and E. coli W3110 in healthy pooled urine as
measured by OD600. The number of independent data points represented is four. Data represent mean and standard deviation values. Source data are
provided as a Source Data ﬁle
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static conditions (STc) for the CAUTI model, this analysis
included bacteria grown in both conditions. Differential proteo-
mic results are shown in Fig. 6b, c and RNAseq results are
shown in Fig. 7a, b, respectively (Supplementary Table 3 and 4,
Supplementary Data 1–5 and Supplementary Figs. 5 and 6).
Proteomic and transcriptional analyses conﬁrmed that pAB5
repressed T6SS in all the tested conditions. In SHc the expression
of components of the CUP2 pili and genes involved in poly-N-
acetyl-β-(1-6)-glucosamine (PNAG) biosynthesis were reduced
by pAB5. PNAG is a surface polysaccharide that plays an
important role in bioﬁlm formation in vitro35. In addition, both
proteomic and RNAseq experiments showed that pAB5 increased
the expression of genes related to glutamate/aspartate transport36
and the outer membrane protein OmpW (D1G37_01455)
(Figs. 6b and 7a). OmpW is involved in iron uptake and colistin
binding in A. baumannii 19606 and ATCC17978 strains36. In
STc, CUP2 and PNAG synthesis were not repressed by pAB5.
However, in these conditions, pAB5 repressed CUP1 pili and
increased levels of putative glutamate/aspartate transport pro-
teins, a T1SS secreted agglutinin RTX toxin (D1G37_00080), and
an adjacently-encoded protein OmpA (D1G37_00085). The RTX
toxin is homologous to the recently described putative RTX toxin
in A. nosocomialis M234. Overall, there was agreement between
our proteomic and transcriptomic results. Our data indicate that
in all experimental conditions tested, T6SS is repressed by pAB5.
However, expression of other factors such as PNAG synthesis,










































fimFcupD cupC cupB cupA
Fig. 3 UPAB1 requires CUP pili to establish CAUTI. a Genetic organization of the CUP1 and CUP2 pili locus. b Transmission electron microscopic images
showing the presence of pili structures in UPAB1 grown 2 by 24 h in static conditions. The pili-like structures were mostly absent in the ΔCUP1,2 mutant
strain. Bars: 500 nm. c The ΔCUP1,2 mutant strain is impaired in the establishment of CAUTI. Each symbol represents an individual mouse. Data shown are
pooled from two independent experiments. For each strain, the median value is shown as the horizontal line. Statistical analyses were performed using the






















Fig. 4 pAB5 is required for the establishment of CAUTI. Each symbol
represents an individual mouse. Data shown are pooled from two
independent experiments with ﬁve mice. For each strain, the median value
is shown as the horizontal line. Statistical analyses were performed using
the Mann–Whitney U test, **p < 0.005, ****p < 0.0001. Source data are
provided as a Source Data ﬁle
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conditions. In conclusion, pAB5 modulates the expression of
several chromosomally-encoded factors that could account for
the differential outcomes in the CAUTI and pneumonia models.
pAB5, but not other LCPs, impact PNAG formation in
UPAB1. PNAG is a surface polysaccharide that is a key virulence
factor in highly divergent bacterial species37,38. A. baumannii
PNAG plays a crucial role in bioﬁlm formation35. Congo red
dye associates with PNAG and is commonly employed to com-
pare PNAG production in A. baumannii35,39. UPAB1p- grown
on Congo red plates showed a clear production of PNAG
(red colonies) while almost no production was observed in WT
UPAB1 (white colonies) (Fig. 8a), validating our transcriptomic
and proteomic data. Plasmids pAB3 and pAB430 are homologous
to pAB5 and share common features, such as a conserved con-
jugation machinery and a regulatory locus containing the two
TetR transcriptional regulators implicated in repressing T6SS30.
However, the plasmids diverge in several regions, and additional
genes putatively encoding transcriptional regulators are present
on pAB5 (Supplementary Fig. 8). To examine whether the TetR
repressors are also responsible for the pAB5-dependent pheno-
types, we conjugated pAB3 and pAB4 into UPAB1. Although











































































































Fig. 5 pAB5 is detrimental in an acute pneumonia murine model. Mice were
intranasally inoculated with 1 × 109 CFU of either the WT UPAB1 or
UPAB1p- strain. Following 36 h of infection, total numbers of CFU recovered
were determined for lungs, spleen, liver, kidneys and heart. Each symbol
represents an individual mouse. Data shown are pooled from two
independent experiments. For each strain, the mean value is shown as the
horizontal line. Statistical analyses were performed using the







































































































































































Fig. 6 pAB5 modulates chromosomally-encoded proteins. Quantitative
proteome analysis of the effect of pAB5 on the secretome (a), the whole
proteome with shaking (b), and whole proteome under static conditions
(c). Manhattan plots demonstrating the signiﬁcance of protein alteration,
–log10(p-value), vs position in the genome are shown. The direction of the
protein alteration is colored coded according the provided heat map.
Selected proteins and accession numbers are shown. Full data sets are
shown in Supplementary Fig. 7. Pink shadow highlights the genes encoding
for CUP1 pili, yellow shadow highlights the genes encoding for CUP2 pili,
orange shadow highlights the genes of PNAG biosynthetic pathway and
green shadow highlights the genes encoding for the T6SS. Four biological
replicates of each condition were analyzed. The default Maxquant FDR
setting of 1% FDR at the protein and peptide levels were used
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Fig. 7 pAB5 differentially modiﬁes the expression of chromosomal genes. DEGs with adjusted p-value < 0.1 for shaking (a) and static (b) grown conditions
are depicted as a volcano plot to show the relationship between Log2 fold change and statistical signiﬁcance. Each circle depicts one gene, upregulated
genes are blue and downregulated genes are red, with the accession number shown for select genes. Pink shadow highlights the genes encoding for CUP1
pili, yellow shadow highlights the genes encoding for CUP2 pili, orange shadow highlights the genes of PNAG biosynthetic pathway and green shadow
highlights the genes encoding for the T6SS. Three biological replicates of each condition were analyzed. All genes in the transcriptomic volcano plot with
adjusted p-values above the statistical cut off of 0.1 (i.e., not signiﬁcantly different between conditions) per the DESeq2 vignette are in gray, while the genes
with adjusted p-values below 0.1 are blue or red
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observed no signiﬁcant repression of PNAG production in bac-
teria conjugated with pAB3 and pAB4 (Fig. 8a). Thus, repression
of PNAG production is not result of TetR expression or ﬁtness
costs caused by plasmid carriage, indicating that additional fea-
tures speciﬁc to pAB5 mediate chromosomal gene repression.
Discussion
Acinetobacter infections are a threat to global health, especially
due to the increasing frequency of MDR infections. Research on
Acinetobacter pathogenesis has almost exclusively focused on
pneumonia and bloodstream infections. In this study, we high-
light the role of A. baumannii as a uropathogen. One in ﬁve
A. baumannii clinical cases are associated with isolation from
urinary sites, demonstrating the ability of this pathogen to persist
in the human urinary tract. We describe strain-speciﬁc differ-
ences in the ability of A. baumannii to replicate in human urine
and to establish colonization of catheterized murine bladders,
with pathophysiology features akin to other well-established
bacterial uropathogens. We established UPAB1 as a model strain
for investigating A. baumannii uropathogenesis and identiﬁed
CUP pili as probable determinants for bladder and catheter
colonization. This model could be very useful for testing the
ability of pilicides to reduce or prevent UTIs by MDR A. bau-
mannii strains. Pilicides are small molecules with a 2 pyridone
backbone that have been shown to inhibit type 1 and P pilus CUP
assembly40. Future work will focus on determining the con-
tribution of each individual CUP pilus in A. baumannii CAUTI.
UPAB1 opens new avenues for studying an important
dimension of Acinetobacter disease. This extensively drug-
resistant strain was isolated from a community-onset UTI in an
Argentinian patient with no prior interaction with local health-
care systems. The strain belongs to an increasingly important A.
baumannii phylogeny, multi-locus sequence type (ST) 25 (Pas-
teur scheme41)/international clone (IC) 7. ST25/IC7 is one of the
most prevalent clonal lineages associated with carbapenem-
resistance and is associated with epidemic, endemic and sporadic
strains isolated in multiple continents, including the Americas42.
Though ST25/IC7 strains have been isolated from multiple
infection sites, one study strongly linked ST25/IC7 to UTIs in
domesticated animals43. Multiple ST25 strains harbor LCPs
similar to pAB544, but LCPs have also been identiﬁed in
A. baumannii urinary isolates belonging to other major interna-
tional lineages45. Thus, investigations performed on UPAB1 are
applicable to a relevant portion of Acinetobacter isolates, and a
validated murine CAUTI model will be an important tool for
developing interventions against the growing tide of MDR UTIs.
Remarkably, we found that the LCP pAB5 has a global inﬂu-
ence on the physiology of UPAB1. pAB5 confers UPAB1 with
improved survival in the urinary tract, but attenuates its virulence
in a pulmonary model, highlighting the relevance of an under-
appreciated feature of bacterial plasmids. LCPs like pAB5 were
previously shown to repress T6SS in its bacterial host30. However,
it was unclear whether LCPs mediate additional effects on gene
expression. Here, we identiﬁed multiple surface molecules and
metabolic pathways whose expression was affected by the pre-
sence of the plasmid, and these regulatory networks could explain
the differential ﬁndings in murine models. In addition to the TetR
regulators shown to be sufﬁcient for T6SS suppression30, pAB5
contains several putative transcriptional factors (Supplementary
Fig. 8) that could directly alter the expression of chromosomally-
encoded factors identiﬁed in our study. Alternatively, a plasmid-
encoded factor might interact with unidentiﬁed, chromosomal
master regulators that in turn impact the bacterial transcriptome.
A third possibility is that presence of the plasmid is intrinsically
sensed by the bacterium, triggering changes in the expression of
several chromosomal factors. This latter scenario is not consistent
with the observation that conjugation of pAB3 and pAB4 into
UPAB1 does not alter PNAG expression. The fact that growth
conditions also inﬂuence expression of virulence factors modu-
lated by pAB5, indicates that pAB5 transcriptional effects are
integrated into the global regulatory network of UPAB1. Viru-
lence plasmids, i.e. plasmids encoding virulence factors, have been
well-studied32,33. Although we cannot exclude the role of a
putative plasmid-encoded virulence factor in CAUTI, our results
show that pAB5 modulates the expression of multiple
chromosomally-encoded factors, effecting the UPAB1 bacterial
surface. Most Acinetobacter strains possess a constitutively active
T6SS. LCP conjugation requires the survival of the recipient,
which is the target of the T6SS. We have recently showed that
T6SS repression by LCP enable plasmid dissemination and the
propagation of MDR among Acinetobacter isolates31. Thus, while
the ability to conjugate may be the driving force behind T6SS
repression by LCP, whether regulation of other chromosomal
factors is beneﬁcial for the plasmid remains to be elucidated.
Bacterial plasmids that control chromosomally-encoded genes
have been reported46,47. However, the broad impact on bacterial
genome expression and pathobiology by pAB5 has not been
reported for any other plasmid. Future work to elucidate the
mechanisms through which pAB5 affects UPAB1 uropathogen-
esis will be needed. Since plasmid biology was largely researched
prior to the “omics” era, revisiting these topics with modern tools
may unveil additional effects that plasmids have on the expres-
sion of virulence factors of other bacteria. Even though the
mechanistic details remain unclear, LCP carriage dictates differ-
ential A. baumannii survival in different host anatomical sites.
Our ﬁndings challenge the dogma that opportunistic pathogens,
such as A. baumannii, are niche nonspeciﬁc, and future investi-
gations into the pathobiology of these bacteria must consider the
clinical context of model strains.
Methods
Bacterial strains and growth conditions. Bacterial strains used in this study are










pAB5 p- pAB3 pAB4
p- pAB3 pAB4 pAB5
Fig. 8 Effects of different LCPs in UPAB1. a Congo red agar plates, showing
differences in the colony color (red versus white) associated with
production of PNAG. b Western blot assays probing for Hcp (green)
expression and secretion in whole-cell (W) or supernatants (S). RNA
polymerase (RNAP, red) was used as a loading and lysis control. Source
data are provided as a Source Data ﬁle
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lysogeny broth (LB) liquid medium at 37 °C with shaking (200 rpm). The anti-
biotics rifampicin (100 µg per ml), kanamycin (7.5 or 15 µg per ml), hygromycin B
(300 µg per ml), chloramphenicol (12.5 μg per ml), sulfamethoxazole (30 μg per ml),
trimethoprim (6 µg per ml) and gentamicin (15 µg per ml) were added when
necessary. Spontaneous rifampicin-resistant mutant strains were obtained by plating
an overnight culture on LB agar with rifampicin.
Local epidemiological analysis. A retrospective study was performed on a cohort
of cases identiﬁed in the BJC Healthcare System (BJC) from January 2007 to
September 2017. Details on this analysis are published elsewhere48. Brieﬂy, all cases
with isolates obtained as a part of regular medical care and identiﬁed as “Acine-
tobacter baumannii” or “Acinetobacter calcoaceticus-baumannii complex” during
the study period, were eligible for inclusion in this study. Both labels were used to
account for differences in reporting methods implemented in the BJC over the
course of this study. Cases identiﬁed solely on surveillance cultures during sus-
pected outbreaks were excluded from the study, and only the ﬁrst non-surveillance
isolate per patient was included in the analysis. Cases were classiﬁed in one of ﬁve
categories according to the anatomical site of isolation: “respiratory”, “skin and soft
tissue/musculoskeletal” (SST/MSK), “urinary”, “endovascular”, or “other.”
Systematic literature review of Ab epidemiology. We performed a literature
search in PubMed using combination of terms “Acinetobacter baumannii”, “Aci-
netobacter”, “epidemiology”, “isolation sites,” and an expanded search using bib-
liographies of identiﬁed studies. Reports published in or after 1995 were then
reviewed in detail for inclusion criteria. For inclusion in our analysis, an epide-
miological study must have fulﬁlled the following criteria: (1) reported isolates as
Acinetobacter baumannii or Acinetobacter calcoaeceticus-baumannii complex, i.e.,
studies that only characterized clinical isolates identiﬁed to the genus level alone
were excluded; (2) performed on consecutive, non-duplicate isolates obtained from
a geographically and temporally associated population; (3) isolates were not
exclusively obtained from a single patient population (e.g., immunocompromised)
or hospital ward (e.g., only ICU patients); and (4) included isolates obtained from
“urinary” sites, and at least two other anatomical sites. Isolates in each study were
then grouped into the ﬁve categories, as above, and enumerated.
Construction of A. baumannii mutant strains. An UPAB1 derivative that
spontaneously loss pAB5 was identiﬁed by detection of restored Hcp secretion49.
Brieﬂy, individual colonies were inoculated in 96-well plates containing LB media
and incubated overnight. Cultures were centrifuged, and 75 μL of supernatants
were transferred into high-binding ELISA 96-well plates containing 25 μL binding
buffer (100 mM sodium bicarbonate/carbonate, pH 9.6). Following overnight
incubation at 4 °C, plates were washed with PBS, blocked, and then probed with
rabbit anti-Hcp antibody. Bound anti-HCP antibodies were detected with HRP-
conjugated goat anti-rabbit antibodies (Bio-Rad) and treatment with 100 μL of
3,3′,5,5′-Tetramethylbenzidine substrate (Cell Signaling Technologies). Cultures
corresponding to wells where Hcp was present were subcloned for individual
colonies with restored Hcp secretion. Loss of pAB5 was conﬁrmed by loss ami-
noglycoside resistance and PCR with pAB5-speciﬁc primers. The primers used in
this study are listed in Supplementary Table 6. Mutants were constructed as
described previously50. Brieﬂy, an antibiotic resistance cassette was ampliﬁed with
150 bp oligonucleotide primers (Integrated DNA Technologies) with homology to
the ﬂanking regions of the targeted gene with an additional 3′ 18–25 nucleotides
of homology to the FRT site-ﬂanked kanamycin resistance cassette from plasmid
pKD451. This PCR product was electroporated into competent UPAB1p- carrying
pAT04, which expresses the RecAB recombinase50. Mutants were selected on 7.5 µg
per ml kanamycin, and integration of the resistance marker was conﬁrmed by PCR.
To remove the kanamycin resistance cassette, electrocompetent mutants were
transformed with pAT03 plasmid, which expresses the FLP recombinase. Spon-
taneous rifampicin-resistant clones of clean deletion mutants were obtained.
Subsequently, pAB5 restoration in mutant strains was achieved by conjugation
using UPAB1 wild type (WT) as donor strain and selection on LB agar containing
gentamicin and rifampicin. Similar conjugation methods were employed to obtain
UPAB1p- derivatives containing pAB3 and pAB4 from donor A. baumannii strains
17978 and AB04, respectively. All mutant strains were conﬁrmed by antibiotic
resistance proﬁle, PCR, sequencing, and Hcp secretion assay (see below).
Murine Model of A. baumannii CAUTI. Six- to 8-wk-old female C57BL/6 mice
were obtained from Charles River Laboratories. Mice were transurethrally
implanted with a small piece of silicone tubing (catheter implant) and inoculated52.
Brieﬂy, mice were anesthetized by inhalation of 4% isoﬂurane, and a 4- to 5-mm
piece of silicone tubing (catheter) was placed in the bladder via transurethral
insertion. Bacterial strains were prepared for inoculation after static growth twice at
37 °C by centrifugation at 6500 rpm for 5 min, washing twice in 1 × PBS, and
resuspension in PBS to the ﬁnal inoculum. When indicated, mice were infected
immediately following implant placement with ∼2 × 108 CFUs bacteria in 50 μL via
transurethral inoculation. At 24 h post-infection (pi), mice were euthanized, and
kidneys, bladders, and implants were aseptically removed. The bacterial load
present in each tissue was determined by homogenizing each organ in PBS and
plating serial dilutions on LB agar supplemented with antibiotics when appropriate.
All CAUTI studies were performed in accordance with the guidelines of the
Committee for Animal Studies at Washington University School of Medicine and
we have complied with all relevant ethical regulations. Mice were housed with a
cycle consisting of 12 h of light and dark with access to standard food and water ad
libitum.
Immunohistochemistry and Histopathology. Bladder sections were depar-
afﬁnized with xylene (two times for 10 min), rehydrated with isopropanol (three
times for 5 min), and washed with water for 5 min. Bladder antigens were exposed
by boiling the section in 10 mM Na-citrate for 45 min and washed in water for
5 min and then PBS three times for 5 min each. Sections were then blocked with
blocking buffer (PBS containing 1% BSA and 0.3% Triton X-100) for 1 h, washed
with PBS containing 0.05% Tween 20 (PBS-T), and incubated with primary anti-
bodies (1:100) overnight at 4 °C. Next, sections were washed three times with PBS,
incubated with secondary antibodies (1:500, Alexa Fluor 488-labeled donkey anti-
goat #A-11055 and Alexa Fluor 647-labeled donkey anti-goat #A-214473) for 1 h at
room temperature, and washed three times with PBS. Lastly, sections were coun-
terstained with Hoechst dye speciﬁc for DNA (1:20,000). A Zeiss Axioskop 2 MOT
Plus microscope was used to analyze the sections via epiﬂuorescence microscopy.
Implants were blocked with blocking buffer (1.5% BSA containing 0.1% sodium
azide in PBS) overnight at 4 °C. Implants were then washed with PBS-T (three
times for 5 min) and incubated with goat anti-ﬁbrinogen and rabbit anti-UPAB1
(1:500) in dilution buffer (PBS containing 0.05% Tween 20, 0.1% BSA, and 0.5%
methyl-α-D-mannopyranoside) at room temperature for 2 h. Implants were
washed with PBS-T (three times for 5 min) and incubated with donkey anti-goat
IRDye 800CW (#926-32214) and donkey anti-rabbit IRDye 680LT (#926-68023)
(diluted 1:10,000) in dilution buffer for 1 h at room temperature. Lastly, implants
were washed with PBS-T (three times for 5 min) and allowed to air dry. The
Odyssey Imaging System (LI-COR Biosciences) was used to examine the infrared
signal. Controls for autoﬂuorescence included nonimplanted catheters.
Murine model of A. baumannii acute pneumonia. All infection experiments
were approved by the Vanderbilt University Institutional Animal Care and Use
Committee and we have complied with all relevant ethical regulations. Mice were
housed with a 12 h/12 h light/dark cycle with access to standard food and water
ad libitum. Lung infection experiments were performed as previously described53.
Brieﬂy, prior to infection, overnight cultures were diluted 1:1000 into 50 mL LB
liquid media and incubated in 250-mL ﬂasks at 37 °C under shaking conditions.
Bacteria in logarithmic growth were harvested by centrifugation, washed twice with
PBS, and resuspended in PBS to ﬁnal inoculum. 9-week-old male C57BL/6 mice
(Jackson Laboratories) were inoculated intranasally with a 7–8 × 108 CFUs of WT
UPAB1 or UPAB1p- in 30 μL PBS. Lungs, livers, spleens, kidneys and hearts were
aseptically harvested from mice euthanized at 36 h post-infection. Bacterial load
was determined by homogenization of each organ and plating serial dilutions
on LB agar.
Hcp Western blotting. Hcp western blots were performed as previously descri-
bed34. Brieﬂy, supernatants and whole cell samples were obtained from mid-log
bacterial cultures. Samples were resuspended in 1X Laemmli buffer and loaded in a
12% polyacrylamide gel for separation. The mouse anti-Hcp54 and rabbit anti-RNA
polymerase (#663104, Biolegend, San Diego, CA) were both used at a concentration
of 1:1000. Secondary IR dye antibodies from Licor were used at 1:10,000 (IRDye
800 CW goat anti-rabbit 926-32211 and IRDye 680 RD goat anti-mouse 925-
68070). All blots were blocked in TBS blocking buffer (Licor).
Genome sequence and annotation. The DNA library of genomic DNA extracted
from UPAB1 (DNeasy Blood and Tissue Kit, Qiagen) was prepared following the
Paciﬁc Biosciences 20 kb Template Preparation Using BluePippin Size-Selection
System protocol. We sheared 7.5 μg of high-molecular-weight genomic DNA (ﬁnal
volume of 100 μL) using the Covaris g-TUBES (Covaris Inc.) at 4500 rpm (1900 ×
g) for 60 s on each side on an Eppendorf centrifuge 5424 (Eppendorf). The sheared
DNA was size selected on a BluePippin system (Sage Science Inc.) using a cutoff
range of 7 kb to 50 kb. The DNA damage repair, end repair, and SMRTbell ligation
steps were performed as described in the template preparation protocol with the
SMRTbell Template Prep Kit 1.0 reagents (Paciﬁc Biosciences). The sequencing
primer was annealed at a ﬁnal concentration of 0.8333 nM, and the P4 polymerase
was bound at 0.500 nM. The library was sequenced on a PacBio RSII instrument at
a loading concentration (on-plate) of 80 pM using the MagBead loading protocol,
DNA sequencing kit 2.0, SMRT cells v3, and 3-h movies. Sequencing was per-
formed at the McGill University and Genome Quebec Innovation Center. Genome
annotation was conducted using the NCBI Prokaryotic Genome Annotation
Pipeline55,56.
Collection of urine. Human urine was collected and pooled from three healthy
female donors between 20–35 years of age. Donors had no history of kidney
disease, diabetes or recent antibiotic treatment. Urine was sterilized using a 0.22 μm
ﬁlter (EMD, Milipore) and adjusted to pH 6.0–6.5 prior to use. All participants
have signed an informed consent and protocols were approved by the local Internal
Review Board.
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Growth assays. Bacteria were cultured overnight in rich liquid media (LB or
brain-heart infusion, BHI) at 37 °C under shaking conditions. Cultures were
washed with PBS and diluted to OD600= 0.01 in 150 µL of either pooled human
urine or rich media in 96 well plates and incubated at 37 °C under shaking
conditions. OD600 values were measured every 30 min for 16 h via a BioTek
microplate spectrophotometer. At least three separate experiments were performed
with three wells per experiment for each strain.
Transmission electron microscopy. For negative staining and analysis by trans-
mission electron microscopy, bacterial suspensions were allowed to absorb for
10 min onto freshly glow-discharged Formvar/carbon-coated copper grids. The
grids were washed in distilled water and stained for 1 min with 1% aqueous uranyl
acetate (Ted Pella Inc., Redding, CA). Excess liquid was gently removed, and grids
were air dried. Samples were viewed on a JEOL 1200EX transmission electron
microscope (JEOL USA, Peabody, MA) equipped with an AMT 8-megapixel digital
camera (Advanced Microscopy Techniques, Woburn, MA).
Secreted protein enrichment for quantitative proteomics analysis. UPAB1 and
UPAB1p- were grown overnight in 5 ml of M9 minimal medium supplemented
with 0.2% casamino acids (M9CA) and subsequently diluted to A600= 0.05 in
50 ml of fresh M9CA. Cultures were incubated to mid-log phase and centrifuged at
15,000 g for 2 min. Supernatants were ﬁlter-sterilized with Steriﬂip vacuum-driven
ﬁltration devices (Millipore), concentrated with an Amicon Ultra (Millipore)
concentrator with a 10-kDa molecular weight cutoff, ﬂash frozen and lyophilized.
Lyophilized samples were then processed for mass spectrometry analysis as
described below. Four individual 50-ml culture biological replicates were prepared
for each strain.
Whole cells samples for transcriptomic and proteomics analysis. Samples were
prepared in the same conditions as the inocula used for the murine pneumonia
model experiments (shaking conditions, SHc), and for the CAUTI model (static
conditions, STc). For SHc samples, overnight cultures were diluted 1:1000 into
50 mL LB liquid media and incubated in 250-mL ﬂasks at 37 °C under shaking
conditions. Bacteria in logarithmic growth were harvested by centrifugation. For
STc samples, overnight cultures grown under static conditions were diluted 1:200
into 15 mL LB liquid media and incubated in 50-mL ﬂasks at 37 °C under static
conditions. Overnight cultures were harvested by centrifugation. Samples for
transcriptomics were resuspended in (RNAprotect Cell Reagent (Quiagen) and
processed as described below. Samples for comparative proteomic analysis were
ﬂash frozen and lyophilized. Lyophilized samples were then processed for mass
spectrometry analysis as described below
Preparation of protein samples for proteomic analysis. Lyophilized supernatant
samples (containing secreted proteins) or lyophilized bacterial pellets were resus-
pended in 4% SDS, 100 mM HEPES, 10 mM DTT and boiled at 95 °C for 10 min
with shaking at 2000 rpm to solubilize protein material. 100 μg of protein, as
determined by BCA protein quantiﬁcation assay (Thermo Fisher Scientiﬁc), was
precipitated by overnight incubation in 80% acetone at −20 °C with shaking.
Precipitated proteins were centrifuged at 10,000 G for 10 mins at 0 °C. To ensure
removal of SDS, resulting pellets were again suspended and incubated overnight in
80% acetone. Precipitated protein pellets were obtained by centrifugation and dried
at 75 °C for 5 mins and stored at −20 °C until analyzed.
Digestion of complex protein lysates. Hundred micrograms of dried protein
pellets were prepared57 with minor alterations. Brieﬂy, dried protein samples were
resuspended in 6 M urea, 2 M thiourea, 40 mM NH4HCO3 and reduced/alkylated
with TCEP/Chloroacetamide (ﬁnal concentration 10 mM and 20mM respectively)
for 1 h in the dark. Samples were pre-digested with Lys-C (1/200 w/w) for 3 h then
diluted to a ﬁnal urea/thiourea concentration below 2M and digested overnight
with trypsin (1/50 w/w). Digested samples were acidiﬁed to a ﬁnal concentration of
0.5% formic acid and desalted with home-made high-capacity StageTips composed
on 5mg Empore™ C18 material (3 M, Maplewood, Minnesota) and 5 mg of OLIGO
R3 reverse phase resin (Thermo Fisher Scientiﬁc) according to the protocol Ishi-
hama and Rappsilber58,59. Using this protocol StageTips were ﬁrst conditions with
10 bed volumes of Buffer B (80% ACN, 0.1% FA) and then equilibrated with 10 bed
volumes of Buffer A* (2% ACN, 0.01%TFA). Peptide samples were loaded onto
columns and columns washed with 10 bed volumes of Buffer A*. Bound
peptides were eluted with buffer B (80% ACN, 0.1% Formic acid), dried and stored
at −20 °C.
Reversed phase LC-MS. Puriﬁed peptides were resuspended in Buffer A* (2%
ACN, 0.01%TFA) and separated using a two-column chromatography set up
comprising a PepMap100 C18 20 mm × 75 μm trap and a PepMap C18 500 mm ×
75 μm analytical column (Thermo Scientiﬁc). Samples were concentrated onto the
trap column at 5 μl/min with buffer A (2% ACN, 0.1% FA) for 5 mins and infused
into either an Orbitrap Elite™ Mass Spectrometer (Thermo Scientiﬁc) or Q-Exac-
tive™ plus Mass Spectrometer (Thermo Scientiﬁc) at 300 nl/min via the analytical
column using Dionex Ultimate 3000 UPLCs (Thermo Scientiﬁc). For comparison
of the effect of the absence vs presence of pAB5, whole cell proteomes samples were
analyzed on the Q-Exactive™ plus using an 125 min gradients altering the buffer
composition from 1% buffer B to 28% B (80% ACN, 0.1% FA) over 95 mins, then
from 28% B to 40% B over 10 mins, then from 40% B to 100% B over 2 mins, the
composition was held at 100% B for 3 mins, and then dropped to 3% B over 5 mins
and held at 3% B for another 10 mins. The Q-Exactive™ plus Mass Spectrometer
was operated in a data-dependent mode automatically switching between the
acquisition of a single Orbitrap MS scan (70,000 resolution) followed by 15 data-
dependent HCD MS-MS events (resolution 35 k AGC target of 2 × 105 with a
maximum injection time of 110 ms, NCE 35) were allowed with 45 s dynamic
exclusion enabled. Four biological replicates of each whole proteome condition
were analyzed in a randomized manner to minimize batch effects. Wash runs were
performed between replicates to prevent samples carry over.
The analysis of the effect of the absence vs presence of pAB5 on the secretome
and under differencing conditions was performed on an Orbitrap Elite™ using an
142 min gradient altering the buffer composition from 1% buffer B to 28% B
over 115 min, then from 28% B to 40% B over 7 , then from 40% B to 100% B over
2 min, the composition was held at 100% B for 3 min, and then dropped to 3% B
over 5 min and held at 3% B for another 10 min. The Elite™ Mass Spectrometer
was operated in a data-dependent mode automatically switching between the
acquisition of a single Orbitrap MS scan (60,000 resolution) followed by ﬁve data-
dependent HCD MS-MS events (resolution 15 k AGC target of 4 × 105 with a
maximum injection time of 200 ms, NCE 35) were allowed with 35 ss dynamic
exclusion enabled. Four biological replicates of each whole proteome condition
were analyzed in a randomized manner to minimize batch effects. Wash runs were
performed between replicates to prevent samples carry over
Proteomic data analysis. MS data were processed using MaxQuant (v1.5.3.3060).
Database searching was carried out against Acinetobacter baumannii UPAB1
(GenBank entry: CP032215, CP032216, CP032217, CP032218, CP032219, and
CP032220). Searchers were undertaken with the following search parameters:
carbamidomethylation of cysteine as a ﬁxed modiﬁcation; oxidation of methionine,
acetylation of protein N-terminal trypsin/P cleavage with a maximum of two
missed cleavages. The default Maxquant FDR setting of 1% FDR at the protein and
peptide levels was used. To enhance the identiﬁcation of peptides between samples,
the Match between Runs option was enabled with a precursor match window set to
2 min and an alignment window of 10 min. For label free quantitation the MaxLFQ
option within Maxquant61 was enabled in addition to the re-quantiﬁcation module.
The resulting outputs were processed within the Perseus (v1.5.0.9)62 analysis
environment to remove reverse matches and common proteins contaminates prior
to further analysis. For LFQ comparisons missing values were imputed with a
downshift of 2.5 and width of 0.3 standard derivations. Statistically assessment
of alterations between conditions was done using two sample t-test within Perseus
with a Benjamini Hochberg correction FDR of 0.05. Pearson correlations and
Perseus outputs were visualized using R (https://www.r-project.org/). The mass
spectrometry proteomics data have been deposited to the ProteomeXchange
Consortium via the PRIDE63 partner repository with the dataset identiﬁer
PXD011302 and PXD011341 which contains all the raw MS data ﬁles and Max-
quant outputs, including the list of all search parameters.
RNA-sequencing extraction and sequencing. Triplicate cultures of WT UPAB1
(UPAB1_pAB5) or UPAB1p- (UPAB1_plasmid-) were grown in LB broth, Lennox
(Fisher Bio Reagents, Cat. No BP1427) to mid-log phase at 37 °C under either
shaking or static conditions. Samples were added to RNAlaterTM stabilization
solution (Thermo Fisher Scientiﬁc, Waltham, MA, USA) and kept at −80 °C until
processing. Total RNA was extracted from the thawed samples with the ZR Fungal/
Bacterial RNA MiniPrepTM kit (Zymo Research, Irvine, CA, USA) using the RNA
protocol following manufactures instructions except with an additional on column
TURBO DNase treatment (Thermo Fisher Scientiﬁc) for 30 min at 37 °C to remove
genomic DNA. Following TURBO DNase treatment, the RNA was puriﬁed in the
RNA Clean & Concentrator kit (Zymo Research). The RNA samples had con-
centration, absorbance values at 260/280 nm, and absorbance values 260/230 nm
analyzed by NanoVue Plus™ Spectrophotometer (GE Healthcare, Chicago, IL,
USA). Contaminating gDNA was analyzed using PCR ampliﬁcation of the 16S
rRNA gene. Approximately 2 μg of RNA was used as input for the Ribo-Zero rRNA
Removal Kit (Illumina, San Diego, CA). The rRNA-free sample was converted into
cDNA libraries using SuperScript II (ThermoFisher Scientiﬁc), DNA Pol I (New
England Biolabs, Ipswich, MA, CA), and DNA ligase (New England Biolabs)64.
cDNA was quantiﬁed using Qubit dsDNA HS assay (ThermoFisher Scientiﬁc). Five
nanograms of DNA was used as input to make Illumina sequencing libraries with
the Nextera XT Kit (Illumina)65.
Transcriptomic analysis. Pooled cDNA libraries were submitted to the Center
for Genome Sciences & Systems Biology at Washington University in St. Louis
School of Medicine. Samples were sequenced on an Illumina NextSeq 550 system
to obtain 1 × 75 bp sequences. Raw reads were demultiplexed by barcodes and had
adapters removed with trimmomatic v.38using the command “java -Xms1024m
-Xmx1024m -jar<trimmomatic_jar>SE -phred33 -trimlog<-
trimlog_output><multiplexed_read><trimmed_read>ILLUMINACLIP:/opt/apps/
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trimmomatic/0.36/adapters/NexteraPE-PE.fa:2:30:10 LEADING:3 TRAILING:3
SLIDINGWINDOW:4:15 MINLEN:36”66. The UPAB1 genome (Accession
CP032215-20) was converted into a bowtie2 v.2.3.4.1 index with command
“bowtie2-build UPAB1.fasta<index>” and the trimmed reads were aligned to it
with command “bowtie2 -x<index>-U<trimmed_read>-S<sam_output>2><bow-
tie2_log>” to generate SAM ﬁles67. Count matrices were generated using Fea-
tureCounts within subread v1.5.3 with command “srun featureCounts
-a<SAF_ﬁle>-F SAF -o<count_output><sam_ﬁle>”68. Differential expression
analysis of the count matrix was performed using DESeq269. Per the DESeq2
vignette (http://bioconductor.org/packages/devel/bioc/vignettes/DESeq2/inst/doc/
DESeq2.html), genes with counts <10 were discarded from differential expression
analysis. Variance stabilizing transformation of read count was analyzed as a
heatmap and principal component ﬁgure. DEG analysis was performed by com-
paring UPAB1 with pAB5 versus UPAB1 cured of pAB5 separately for shaking and
static growth. Per the DESeq2 vignette, genes with adjusted p-values <.1 were
determined to be signiﬁcantly differentially expressed.
PNAG detection by Congo Red plates. The colony morphology of A. baumannii
strains was studied on plates containing Congo red agar composed of SOBG media
(SOB media+2% glycerol) supplemented with 40 µg/ml of Congo red (Sigma
Chemical Co., St. Louis, MO)35,70. Plates were incubated at 28 °C for 24 h. On these
plates PNAG-synthesizing cells produced red colonies, whereas PNAG-deﬁcient
cells produced white colonies.
Statistical analysis. All statistical analyses were performed using GraphPad Prism
(GraphPad Software Inc., La Jolla, CA). For comparison of bacterial load in the
murine CAUTI model, statistical analyses were performed using the
Mann–Whitney U test. For the murine acute pneumonia model, data were log
transformed and analyzed for Gaussian distribution using the D’Angostino-Pear-
son omnibus normality test. Data sets displaying Gaussian distribution were then
analyzed by one-way ANOVA with Tukey’s test for multiple comparisons. Data
sets displaying non-Gaussian distribution were analyzed by Kruskal-Wallis test
with Dunn’s test for multiple comparisons. For all other assays, normal data dis-
tribution was checked with the Shapiro-Wilk normality test. For normally dis-
tributed datasets, parametric one-way ANOVA was performed with Tukey’s
correction for multiple comparisons. For non-normally distributed datasets, non-
parametric Kruskal-Wallis test with Dunn’s correction for multiple comparisons
was used.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that data supporting the ﬁndings of this study are available within
the paper and its supplementary ﬁles. The source data underlying Figs. 1, 2, 3b, c, 4, 5, 8
and Supplementary Figs. 1, 2, 3 and 4 are provided as a Source Data ﬁle. The whole-
genome sequence project was deposited in the Sequence Read Archive (SRA) at the
National Center for Biotechnology Information (NCBI) under the accession number
PRJNA487603, and the whole-genome sequences were deposited in the GenBank
database under the accession numbers CP032215 to CP032220. Processed RNA-seq
reads have been submitted to the Short Read Archive under BioProject PRJNA499107.
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